Alkermes (ALKS) Earnings Date & Reports

Key Takeaways

• Alkermes reported third quarter 2026 total revenue of $480.1 million, up about 22% from $394.2 million in the prior-year period.
• Diluted earnings per share (EPS) came in at $0.09, beating the consensus estimate of a loss of $0.08 per share, while revenue also topped the $463.35 million consensus.
• Proprietary product net sales rose 31.5% year over year to $417.3 million, led by the newly added sleep medicine LUMRYZ, which contributed $89.9 million.
• GAAP (Generally Accepted Accounting Principles) net income fell to $16.3 million from $82.8 million a year earlier, weighed down by Avadel acquisition-related costs and higher expenses.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was $120.1 million, and the company reiterated its full-year 2026 financial expectations.
• For more information on this ticker's major news, today's price move, price targets, and forecast, explore our Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover new trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Alkermes is in the middle of a strategic transformation, having closed its acquisition of Avadel Pharmaceuticals in mid-February 2026, which brought the once-nightly sleep medicine LUMRYZ into its commercial portfolio. That deal reshaped the company's product mix, adding a fourth proprietary brand alongside established franchises in addiction and psychiatry. The third quarter results offer investors an early read on how well LUMRYZ is integrating and scaling, while also testing the resilience of Alkermes' older products. With acquisition-related accounting costs clouding GAAP profitability, the report's key signals come from revenue momentum, prescription trends, and adjusted profitability, all of which help clarify whether the company can fund its growing research pipeline while sustaining commercial growth.

Reported Results

For the quarter ended September 30, 2026, Alkermes generated total revenue of $480.1 million, up from $394.2 million in the same period last year. Proprietary product net sales climbed 31.5% to $417.3 million. VIVITROL delivered $127.6 million, ARISTADA $103.9 million, LYBALVI $95.9 million, and the newly acquired LUMRYZ contributed $89.9 million. Manufacturing and royalty revenue was $62.9 million, down from $76.8 million a year ago.

GAAP net income declined to $16.3 million from $82.8 million, reflecting higher costs tied to the Avadel transaction, including about $29.8 million in acquisition-related costs and $19.7 million in amortization of acquired intangible assets. Diluted EPS was $0.09, compared with $0.49 a year earlier, but well above the consensus estimate of a $0.08 loss. Adjusted EBITDA was $120.1 million versus $121.5 million in the prior-year quarter. The company ended the period with approximately $787.6 million in cash and total investments and reiterated its full-year 2026 guidance across all line items.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven moves like Alkermes', it can surface names with similar setups or momentum characteristics. Explore the AI Screener to streamline your own market research.

Market Reaction and Investor Sentiment

The results beat consensus on both the top and bottom lines, with EPS of $0.09 far exceeding the expected loss of $0.08 per share and revenue topping estimates. That upside was driven by strength in proprietary product sales, particularly the rapid ramp of LUMRYZ, which reached roughly 4,100 patients on therapy by quarter end. Still, investor interpretation was nuanced, because GAAP profitability declined sharply year over year due to acquisition accounting and stepped-up operating expenses. Sentiment likely hinges on whether the market focuses on the underlying demand growth and reiterated guidance or on the near-term dilution to reported earnings from the Avadel integration. The mixed signal between strong revenue and lower GAAP net income could temper enthusiasm even after the headline beat.

Forward Outlook and Key Factors to Monitor

Alkermes reiterated its 2026 financial guidance and offered early color on 2027. Management expects proprietary product net sales of $400 million to $420 million in the fourth quarter, implying continued momentum into year end. For 2026, the proprietary portfolio is expected to deliver net sales of nearly $1.6 billion.

Several items deserve attention in the quarters ahead. First, the company anticipates a lower cost of goods sold (COGS) profile in 2027 as the non-cash inventory fair-value step-up tied to the Avadel acquisition rolls off. That should help normalize margins. Second, LYBALVI's gross-to-net deductions, which reached about 42% in the quarter, are expected to rise toward roughly 45% in 2027 as the company expands payer access. Investors will watch whether prescription volume growth, which management sees approaching 20% year over year, offsets that pricing pressure.

On the pipeline side, Alkermes is advancing its orexin receptor agonist portfolio, with Phase III BRILLIANCE studies for elixorexin in narcolepsy underway and top-line results expected beginning in mid-2027. Data from the Phase II VIBRANCE-3 study in idiopathic hypersomnia (IH, a disorder of excessive daytime sleepiness) could also shape the registration path. Balancing rising research and development spending against strong cash generation and adjusted EBITDA will be a central theme as the company invests in its next wave of growth drivers.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations